Growth Through Acquisition FHI Clinical's recent acquisition of TCD Global indicates an active expansion strategy, offering potential cross-selling opportunities for complementary research services and broadening their market reach in complex clinical trials.

Specialized COVID-19 Expertise FHI Clinical has developed significant capabilities in conducting COVID-19 related immunotherapy trials, positioning them as a preferred partner for organizations seeking specialized expertise in infectious disease clinical research.

Global Clinical Footprint With experience managing studies across nearly 75 countries and a team of approximately 450 staff, FHI Clinical is well-positioned to offer international trial management, appealing to clients seeking global trial solutions.

Mid-Size Revenue Range Operating within a revenue range of $50M to $100M, FHI Clinical presents a lucrative target for partnerships or service contracts aimed at mid-sized pharmaceutical and biotech firms looking for customizable CRO solutions.

Technology and Innovation Utilizing advanced tools like Microsoft Power Automate and Deltek Time & Expense, FHI Clinical demonstrates a commitment to streamlining clinical operations, which offers potential for clients interested in integrating innovative tech solutions.